THEY called it the second summer
of love. Twenty years ago, young people all over the
world donned T-shirts emblazoned with smiley faces
and danced all night, fuelled by a molecule called
MDMA. Most of these clubbers have since given up
ecstasy and are sliding into middle age. The
question is, has ecstasy given up on them?
Enough time has finally elapsed
to start asking if ecstasy damages health in the
long term. According to the biggest review ever
undertaken, it causes slight memory difficulties and
mild depression, but these rarely translate into
problems in the real world. While smaller studies
show that some individuals have bigger problems,
including weakened immunity and larger memory
deficits, so far, for most people, ecstasy seems to
be nowhere near as harmful over time as you may have
been led to believe.
The review was carried out by
the UK
Advisory Council on the Misuse of Drugs (ACMD),
an independent body that advises the UK government
on drug policy. Its headline recommendation is that,
based on its harmfulness to individuals and society,
MDMA should be downgraded from a class A drug - on a
par with heroin and cocaine - to class B, alongside
cannabis.
Nobody is arguing that taking
ecstasy is risk-free: its short-term effects are
fairly uncontroversial. MDMA is toxic, though not
powerfully so - an average person would need to take
around 20 or 30 tablets to reach a lethal dose. And
for a small fraction of people, even small amounts
of ecstasy can kill. For example, around half a
million people take ecstasy every year in England
and Wales, and 30 die from the acute effects, mostly
overheating or water intoxication.
What has been unclear, however,
is whether ecstasy use causes long-term health
problems and if so, how much you would need to take
to be at risk.
In animal studies the drug has
been shown to inflict lasting damage to the brain's
serotonin system, which is involved in mood and
cognition. Imaging studies have found signs of
similar damage in human users, but there are debates
over whether this is caused by ecstasy use and
whether the damage has any real-life consequences.
The ACMD based their review
largely on a study they commissioned from Gabriel
Rogers and Ruth Garside of the
Peninsula Medical School in Exeter, UK. They
pulled together all the research from around the
world that attempted to assess the health of people
who have taken ecstasy, and reanalysed the data from
the 110 studies that dealt with long-term effects.
They found that compared with
non-users, people who took even a small amount of
ecstasy at some point consistently performed worse
on psychometric tests, which measure mental
performance, especially memory, attention, and
executive function, which includes decision-making
and planning.
The most pronounced effects are
on memory, mainly verbal and working memory. While
the ability to plan is somewhat affected, other
aspects of executive function are not. Focused
attention - the ability to zoom in quickly on a new
task - suffers too, though sustained attention does
not.
It is a similar story with
depression. "There's a small but measurable effect,"
says Rogers.
These effects appear not just in
current users but also in ex-users who haven't
touched the drug for at least six months, suggesting
that the problems are long-lasting. Strangely, there
seems to be no link between the quantity taken and
the severity of cognitive problems, suggesting that
even a few doses can lead to these deficits.
Superficially, this adds up to a
pretty depressing outlook for the e-generation,
especially those who dabbled years ago but have
since quit. Not so, says Rogers. Subtle differences
in lab tests do not necessarily translate into
real-life problems: "They're statistically
significant, but whether they are clinically
significant is another matter."
Subtle differences on lab tests do not
necessarily translate into problems
in real life.
For example, there is little
evidence that people are actually
affected by the memory and attention
deficits picked up in the lab tests.
"They don't seem to be very big and
it is not clear that they have much
effect on day-to-day functioning,"
he says.
Meanwhile, people who have taken
ecstasy are, on average, still within the normal
bounds on standard depression tests. Although they
score worse than people who haven't taken ecstasy,
the scores aren't bad enough to warrant a diagnosis
from a doctor. "There's no indication that they are
drifting out of normal functioning," says Rogers.
He also warns that his results
need to be taken with a pinch of salt because most
studies are based on self-reports of ecstasy use,
often combined with other drugs and alcohol, from
people who have volunteered to take part. These
confounding factors make it impossible to determine
whether you have a representative sample of users,
whether people's reported use correlates with how
much they actually took and what effects can be
blamed on MDMA.
Psychopharmacologist Val Curran
of University College London says Roger's analysis
"is about the best you can make of the overall
mishmash". She agrees with his conclusion that on
average there seems to be no evidence of any
meaningful effects on daily life.
Others have a different take on
it. Andrew Parrot of the University of Swansea, UK,
who has been studying the health of ecstasy users
since the mid-1990s says: "We see users who have
taken bucket-loads and they have very severe
problems." These include memory deficits, sleep
disturbances, depression, weakened immunity and
sexual dysfunction, he says.
Based on his own studies, he
believes that almost everyone who has taken 20
tablets in total, or more, reports niggling problems
in daily life. "All fairly minor on their own, but
you're ending up with someone who is not as healthy
as they ought to be," he says.
Rogers admits that because he
took averages of such large numbers of users, his
analysis may have "ironed out" some of the effects
Parrot describes.
Parrot also calls ecstasy a
"gateway" drug. "Former users are often heavy users
of alcohol, tobacco and cannabis. When you move off
ecstasy, you look for other drugs. Ecstasy use leads
to other, more problematic drugs."
Despite this, however, results
from the first "prospective" studies are more
encouraging. These studies follow a group of people
over many years and watch the effects of ecstasy
unfold over time. Crucially, they are more reliable
than "retrospective" studies because they don't rely
on people remembering what they did in the past.
In 2002
a group in the Netherlands recruited 188 young
people who had never taken ecstasy but were likely
to in the future. When they retested them on a
battery of psychometric tests three years later, 58
said they had taken ecstasy at least once, giving
the researchers an opportunity to compare cognitive
performance before and after ecstasy.
They found that on all the tests
except for verbal memory, ecstasy users performed
just as well as before, and on a par with abstainers
(Archives
of General Psychiatry, vol 64, p 728). The
results chime with Rogers's conclusions: because the
effect was so small - a difference of a quarter of a
word on average from a list of 15 - the real world
implications are questionable. Brain imaging
revealed no changes to the serotonin system,
although there were signs of damage to white matter
and blood vessels. The practical significance of
this is not yet known (Brain,
DOI: 10.1093/brain/awn255).
On all the tests except those for verbal
memory, ecstasy users performed on a
par with abstainers
Rogers cautions that it is too
soon to give ecstasy the all-clear in the long term,
not least because some effects on health might
simply kick in even later. "It's possible that
ecstasy has horrific consequences later in life.
Only time will tell."